Notícias e Atividades da Cellectis

Cellectis é uma empresa listada sob o símbolo CLLS (FR).

Veja o organograma con seus 17 executivos principais

Biografias mais buscadas da Cellectis

• André Choulika, Chief Executive Officer and Director
• Rainer Boehm, Director
• Axel-Sven Malkomes, Director

Criar um alerta
para seguir os movimentos de executivos da Cellectis.

Cellectis possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Cellectis

• Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing | Cellectis
• Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018 | Cellectis
• CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board | Cellectis
• Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP | Cellectis
• Calyxt Names Biotech Veteran and Board of Directors Member Dr. Yves J. Ribeill as Interim CEO | Cellectis
• Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer | Cellectis
• Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 | Cellectis
• Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018 | Cellectis
• Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports | Cellectis
• Shareholders’ General Meeting of June 26, 2018 | Cellectis
• View more press releases Close

Redes sociais sobre Cellectis

• Cellectis na Wikipedia, Google News e Yahoo Finance
• Cellectis na LinkedIn, Twitter e YouTube